Clinical trials: Retinal Disorders
Age-related Macular Degeneration (AMD)
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life.
- Trial name
- MEDIAL (NCT03577041)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety
This is a Phase IV, randomized, open-label, active-controlled, 2-arm, multicenter study. The primary objective was assessed by the difference in the mean number of ranibizumab injections applied up to Month 11 between the 2…
- Trial name
- ZIPANGU (NCT02953938)
- Testing
- Ranibizumab, Grid&Direct short pulse laser photocoagulation
- Where
- 7 sites in Japan
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy Visually Threatening
Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy
Subject/Participant Groups: Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment Control Group: Subjects do not undergo ILM peeling during…
- Trial name
- NCT04380064
- Testing
- ILM Peeling, No ILM Peeling
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- Rush Eye Associates
Macular Edema, Retinal Vein Occlusion
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent…
- Trial name
- NCT01442064
- Testing
- Ranibizumab 0.5 mg
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Amaurosis, Retinal Diseases
Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy
Retinal dystrophies are responsible for numerous cases of blindness, and there are no therapeutic possibilities today. Gene therapy is efficient in a dog model concerning dystrophy linked to a mutation of the rpe65 gene.
- Trial name
- NCT00422721
- Testing
- realization of a family tree, refractometry, evaluation of the presence of a nystagmus
- Where
- France
- Volunteers
- 360 people
- Sponsor
- Nantes University Hospital
Cataract
Symfony Intraocular Lens Retrospective Chart Review
Retrospective chart review of patients with pre-existing ocular pathology who underwent cataract surgery with implantation of the Symfony IOL.
- Trial name
- NCT05111106
- Testing
- Symfony IOL
- Volunteers
- 463 people
- Sponsor
- Austin Eye
Primary Open Angle Glaucoma
Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Glaucoma is the second leading cause of blindness among seniors in Canada. It is often associated with an elevated intraocular pressure (IOP), but its exact mechanism is still largely unknown.
- Trial name
- NCT01711177
- Testing
- travoprost
- Where
- Canada
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Université de Montréal
Retinal Disease
SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)
This is a randomized, double-masked study to evaluate the tolerability and safety of IRX-101 versus 5% povidone-iodine (PI) in subjects receiving intravitreal anti-VEGF injections.
- Trial name
- RELIEF (NCT05747430)
- Testing
- IRX-101, Providone-Iodine
- Where
- 7 sites in United States
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- iRenix Medical, Inc.
Lutein and Zeaxanthin Dietary Intake, Age Related Macular Degeneration
Online Validation of Dietary Intake Food Frequency Questionnaire Over Four Weeks, and Electronic Device Use Questionnaire Over Eight Weeks.
Tools to investigate dietary lutein and zeaxanthin (L/Z) intake and electronic device (ED) use are important to progress research that investigates the role of ED blue light (BL) exposure, and dietary L/Z intake on macular…
- Conditions
- Lutein and Zeaxanthin Dietary Intake, Age Related Macular Degeneration, Blue Light Exposure, Electronic Device Use
- Trial name
- NCT04779411
- Testing
- Weekly Food Frequency Questionnaire, Monthly Food Frequency Questionnaire, 24-Hour Diet Recall
- Where
- Australia
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- The University of Queensland
Hiv, Coronary Artery Disease
ARIA to Predict Coronary Artery Disease in HIV-infected Individuals
With effective anti-retroviral therapy, non-communicable diseases, such as cardiovascular diseases, have become the major cause of morbidity and mortality for people living with HIV.
- Trial name
- NCT03874221
- Where
- Hong Kong
- Volunteers
- 120 people
- Sponsor
- Chinese University of Hong Kong
Iris Neovascularization, Diabetic Retinopathy
A Pilot Study for the Treatment of Iris Neovascularization With Macugen
The purpose of this study is to determine if a drug called Macugen may help to stop the growth of abnormal blood vessels on the iris that has occurred in the eye(s) as part of diabetic retinopathy.
- Trial name
- NCT00295828
- Testing
- Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hermann Eye Center
Age-Related Macular Degeneration
AMD Ryan Initiative Study (ARIS)
Objective: To learn more about AMD. Eligibility: People ages 55 and older with any of the following: Early AMD RPD Healthy eyes Design: Participants will be screened with: Eye exam: The pupil will be dilated with eye drops.
- Trial name
- NCT03092492
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Eye Institute (NEI)
Diabetic Non-proliferative Retinopathy, Type2 Diabetes
Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy
This study include 384 Participants with diabetic non-proliferative retinopathy Design Method: Randomized, double blind, placebo controlled and multicenter clinical study.
- Trial name
- NCT03025399
- Testing
- Tangwang prescription
- Volunteers
- 384 people
- Sponsor
- Fengmei Lian
Choroideremia, X-Linked Retinitis Pigmentosa
Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa
The objective of the study is to evaluate the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111 and who have exited an…
- Trial name
- SOLSTICE (NCT03584165)
- Testing
- BIIB111, BIIB112
- Where
- 25 sites in United States, Brazil and 7 more
- Volunteers
- 277 people
- Sponsor
- NightstaRx Ltd, a Biogen Company
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705607
- Testing
- MK-8748, Aflibercept
- Where
- 19 sites in United States
- Volunteers
- 1,104 people
- Sponsor
- Merck Sharp & Dohme LLC
Retinopathy of Prematurity
Iron and Retinopathy of Prematurity (ROP)
The purpose of this study is to determine whether increased transferrin saturation in plasma (that reflects iron overload and/or low transferrin) is an independent risk factor for ROP development and severity.
- Trial name
- Fer-ROP (NCT05133999)
- Testing
- Plasma determination of iron, transferrin and ferritin, Fundus Examination by wide field digital imaging camera (PanocamTM camera)
- Where
- 3 sites in France
- Volunteers
- 175 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Geographic Atrophy
Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525600
- Testing
- APL-2
- Where
- 141 sites in United States, Argentina and 13 more
- Volunteers
- 621 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Epiretinal Membrane
Visual Acuity and Optical Coherence Tomography One Year After Peeling of Epiretinal Membranes
Improvement in visual acuity and retinal anatomy one year after surgery is assessed and compared to data preoperative and 3 months after surgery
- Trial name
- NCT03583632
- Testing
- visual acuity testing, optical coherence tomography
- Where
- Austria
- Volunteers
- 75 people
- Sponsor
- Vienna Institute for Research in Ocular Surgery
Retinopathy of Prematurity (ROP)
Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090
This is a follow-up study to evaluate the long term outcome of babies treated in the FIREFLEYE study.
- Trial name
- FIREFLEYE next (NCT04015180)
- Testing
- Eylea (Aflibercept, BAY86-5321), Laser photocoagulation
- Where
- 55 sites in Argentina, Belgium and 22 more
- Volunteers
- 100 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.